SPECTAlung (EORTC 1335)
Research type
Research Study
Full title
SPECTAlung: Screening Patients with thoracic tumors for Efficient Clinical Trial Access
IRAS ID
213461
Contact name
Sanjay Popat
Contact email
Sponsor organisation
European Organisation for the Research and Treatment of Cancer (EORTC)
Duration of Study in the UK
5 years, 1 months, 30 days
Research summary
The aim of this screening program is to test thoracic cancer patients for multiple tumour characteristics/biomarkers (biological molecules that are signs of normal or abnormal process), which will hopefully enable them to be offered access to drugs that specifically target the characteristics of their tumour, in particular within clinical trials. This matching or "personalising of treatment", aims to improve outcomes for individual patients. These trials may be already ongoing or will be planned in the future.
Another objective of this study is to correlate some of the biological information on the tumour with the general tumour characteristics and the patient’s clinical data. This is done by collecting data over many years, and is unrelated to screening for clinical studies.REC name
HSC REC A
REC reference
16/NI/0178
Date of REC Opinion
1 Sep 2016
REC opinion
Further Information Favourable Opinion